Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | KarMMa: idecabtagene vicleucel QoL

Michel Delforge • 15 Jun 2020
EHA 2020
Multiple Myeloma bb2121 CAR-T Idecabtagene vicleucel
KarMMa

Michel Delforge, MD, PhD, of the University of Leuven, Leuven, Belgium, discusses results from the KarMMa trial (NCT03361748) which investigated the quality of life in patients with relapsed and refractory multiple myeloma treated with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Michel Delforge

2:20
HRQoL in heavily pretreated patients with MM treated with ide-cel or standard regimens in KarMMa-3
Michel Delforge • 10 Dec 2023
2:16
Moving CAR-T therapy into the frontline setting in myeloma: insights into CARTITUDE-5 & CARTITUDE-6
Michel Delforge • 4 Oct 2023
1:50
How might inequalities in access to CAR-T therapy for multiple myeloma be addressed?
Michel Delforge • 4 Oct 2023
8:28
Treatment selection for patients with multiple myeloma at first relapse and beyond
Michel Delforge • 4 Oct 2023

Related Videos

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals